Tarsus Pharmaceuticals, Inc. TARS Accrued royalty payable
Accrued royalty payable at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:AccruedRoyaltyPayableCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accrued royalty payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s accrued royalty payable?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accrued royalty payable of $7.27M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accrued royalty payable changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accrued royalty payable increased by 85.6% year-over-year, from $3.92M to $7.27M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accrued royalty payable?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s accrued royalty payable has grown at a 273.0% compound annual growth rate (CAGR), from $654K to $9.1M.
- What does accrued royalty payable mean?
- This captures the current portion of royalty obligations owed to third parties, typically resulting from licensing agreements for intellectual property or drug development rights. It represents a recurring operational expense that directly impacts net margins as commercial products generate revenue. Tracking this is essential for understanding the company's ongoing cost-of-goods or operating expense structure related to licensed technology.